Research technicians

Jeanelle Tsai, BA, ( works on identifying genes that cause drug resistance in EGFR-mutant NSCLCs using a genome-wide CRISPR activation screening system. She is assessing the efficacy of targeting those genes in vitro with the goal of eliminating minimal residual disease (MRD). 

Soumya Malhotra, BA, MS (  works on EGFR, ALK, KRAS and ROS mutant NSCLC cell lines with a goal to identify drug therapies targeting persister cells. Soumya also works with patient samples and PDX to develop in vitro 2D and 3D NSCLC models. 

Mustafa Al-Dulaimi, BS, ( works on investigating the impact of different combinations of RTKi treatments with the goal of overcoming and preventing acquired resistance to EGFR-targeted therapies in EGFR-mutant NSCLC. He also works on identifying targeted therapy options for mesotheliomas by researching potential therapeutic vulnerabilities.